Fig. 3: Clinically relevant oncology combination screen (CROCS) on MPM PDX tumors using HTDBP to identify hits.

Malignant pleural mesothelioma PDX tumors were dissociated, treated with CROCS and HTDBP carried out. Cells were analyzed as previously described in Fig. 1. a Malignant pleural mesothelioma PDX tumors (CPDM_0011x, CPDM_0106x and CPDM_0184x) were implanted subcutaneously in the right and left flank of immunocompromised SCID-bg mice. When the right (RF) and/or left flank (LF) tumor reached 1000 mm3 mice were sacrificed and tumors harvested for CROCS HTDBP. b Venn diagram show the overlap between the CROCS HTDBP hits for MPM patient and PDX samples. c Heatmap showing ranked (highest at the top) Z-score across MPM PDX tumors harvested in (a), for each drug treatment. Blue represents a hit with a Z-score ≥ 3 and yellow are non-hits. d Graphs show mean Z-score for each drug treatment, for individual MPM PDX tumor harvested in (a). One tumor for CPDM_0106x and CPDM_0184x models and four tumors for CPDM_0011x model. Each individual dot represents a different drug treatment (single agent or drug-drug combination). A red dot represents a hit with a Z-score ≥ 3 with no replicate <1.5. Black dots are non-hits. e Graph showing mean Z-score for top ten most common hits and f hits with highest mean across n = 6 MPM PDX tumors.